Resources from the same session
LBA4 - Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Presenter: Pasi Jänne
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
LBA5 - A phase 2 study of neoadjuvant SHR-1701 with or without chemotherapy (chemo) followed by surgery or radiotherapy (RT) in stage III unresectable NSCLC (uNSCLC)
Presenter: Yi-Long Wu
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant
Presenter: Natasha Leighl
Session: Proffered Paper session
Resources:
Slides
Webcast
56O - A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in resectable stage IIIA and IIIB(T3N2) non-small-cell lung cancer
Presenter: Jie Lei
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
1O - IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Presenter: Enriqueta Felip
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant
Presenter: Solange Peters
Session: Proffered Paper session
Resources:
Slides
Webcast
58O - Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III non-small-cell lung cancer (NSCLC): interim analysis from the PACIFIC-R study
Presenter: Nicolas Girard
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
57O - Randomized Double-Blind Phase II Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC: Primary Results
Presenter: Solange Peters
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast